MedPath

Measurement of the Electromechanical Window to Improve the Diagnosis of Congenital Long QT Syndrome

Not Applicable
Completed
Conditions
Long QT Syndrome
Registration Number
NCT04328376
Lead Sponsor
University Hospital, Bordeaux
Brief Summary

The goal of this research is to prospectively evaluate the performance of the electromechanical window according to a phonographic method, as a mean of diagnosis of long QT syndrome, and to compare its performance with routine tests used.

Detailed Description

Familial long QT syndrome (LQTS) is a hereditary cardiac disorder in which most affected family members have delayed ventricular repolarization manifest on the electrocardiogram (ECG) as QT prolongation. This disease is associated with an increased propensity to palpitations, syncope, polymorphous ventricular tachycardia and sudden arrhythmic death. The diagnosis relies mostly on resting ECG findings and on genetic testing. In clinical practice however, this diagnosis is complicated by 2 main reasons: 1) a significant overlap in ECG findings between healthy and diseased individuals and 2) a frequent identification of genetic variants of unknown significance. Recent studies have suggested that echocardiographic measurement of the electromechanical window (EMW - the delay between the end of mechanical contraction and electrical activation of the heart) has better performance in the diagnosis of LQTS. The echocardiographic technique is however too complicated for routine clinical use. Preliminary work conducted at the University Hospital of Bordeaux and at the University Hospital of Reunion Island has demonstrated that a phonocardiographic approach leads to similar results with an improved feasibility and a good reproducibility.

Recruitment & Eligibility

Status
COMPLETED
Sex
All
Target Recruitment
224
Inclusion Criteria
  • Propositus patients with genetically proven LQTS and their relatives,
  • Patients of both sexes aged 12 and over,
  • Free, informed and written consent of the patient and the two holders of parental authority for minors.
Exclusion Criteria
  • Inability to consent,
  • Person deprived of liberty by judicial or administrative decision,
  • Majors subject to a legal protection measure,
  • Person participating in another research including an exclusion period still in progress,
  • Severely impaired physical and / or psychological health, which, according to the investigator, may affect the participant's compliance with the study.

Study & Design

Study Type
INTERVENTIONAL
Study Design
SINGLE_GROUP
Primary Outcome Measures
NameTimeMethod
Negative predictive value (NPV) obtained by the two methods of diagnosisDay 1

The NPV is measured in percentage. The NPV of LQTS diagnosis obtained by phonocardiographic method (measurement of the EMW) and the NPV obtained by standard ECG method (QT measurement prolongation) will be compared.

Secondary Outcome Measures
NameTimeMethod
Values of sensitivity obtained by the two methods of diagnosisDay 1

Value of sensitivity is measured in percentage. The values of sensitivity of EMW and standard ECG will be compared.

Positive predictive values obtained by the two methods of diagnosisDay 1

Positive predictive value is measured in percentage. Positive predictive values of EMW and standard ECG will be compared.

Values of specificity obtained by the two methods of diagnosisDay 1

Value of specificity is measured in percentage. The values of specificity of EMW and standard ECG will be compared.

Area Under the Curves (AUC) obtained by the two methods of diagnosisDay 1

The AUC obtained by Receiver Operating Characteristic (ROC) analyses is measured by a value between 0 and 1.

The AUC obtained by ROC of EMW and standard ECG will be compared.

Trial Locations

Locations (4)

Nantes University Hospital

🇫🇷

Nantes, France

Bordeaux University Hospital

🇫🇷

Pessac, France

La Réunion University Hospital

🇫🇷

Saint-Pierre, France

Toulouse University Hospital

🇫🇷

Toulouse, France

Nantes University Hospital
🇫🇷Nantes, France

MedPath

Empowering clinical research with data-driven insights and AI-powered tools.

© 2025 MedPath, Inc. All rights reserved.